Psoriatic Arthritis Market to Benefit Profoundly at a 6.5% CAGR During the Study Period [2018-2030]; Investment in Research Picks Up, States DelveInsight

LAS VEGAS, June 29, 2021 /PRNewswire/ -- DelveInsight's "Psoriatic Arthritis (PsA) Market" report provides a thorough comprehension of the Psoriatic Arthritis historical and forecasted epidemiology and the Psoriatic Arthritis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Psoriatic Arthritis market report also proffers an analysis of the current Psoriatic Arthritis treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

 Some of the necessary takeaways from the Psoriatic Arthritis Market Research Report 

• Several key pharmaceutical companies include AbbVie, Amgen, Pfizer, Bristol-Myers Squibb, Janssen Biotech, Eli Lilly and Company, Novartis, UCB, Sun Pharma Global FZE, AltruBio, and others, are developing novel products to improve the Psoriatic Arthritis treatment outlook. 
• AbbVie holds the highest Psoriatic Arthritis therapeutic market position among all the current pharma players due to its strategic launch of two candidate drugs Rinvoq and Skyrizi, in the upcoming years. Both the drugs are already approved in the US and EU markets. Also, Skyrizi is already approved in Japan. 
• Psoriatic Arthritis market growth to be ramped up because of the increased prevalence and growth in the awareness and change in lifestyles that have necessitated the changes in the diagnosis and treatment of Psoriatic Arthritis in the recent decade. The development of disease models, which might help in the understanding of Psoriatic Arthritis pathophysiology. In addition, the approval of the multiple drugs has resulted in the entry of the seven different mechanisms of action into the Psoriatic Arthritis market, which has increased the patient response and a change in prescription patterns. 
• Nevertheless, the Psoriatic Arthritis market growth is threatened by underdiagnosis or misdiagnosis and limited current Psoriatic Arthritis treatment options in terms of long-term efficacy, tolerability, safety, route of administration, and cost. The entry of the biosimilars has been delayed, and multiple companies have not launched their generics and biosimilars due to the patent rivalry. Safety concerns around JAK inhibitor class have led to regulatory decisions around Rinvoq being delayed for a second time.

For further information on Market Impact by Therapies, visit: Psoriatic Arthritis Drugs Market Analysis 

Psoriatic Arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. It can present with oligoarticular joint involvement that is typically asymmetric or as a polyarticular disease affecting five or more joints, usually with an asymmetric distribution similar to that of rheumatoid arthritis.

As per DelveInsight's estimates, the total Psoriatic Arthritis prevalent cases in 7MM in 2020 was 1,486,869 cases, out of which the highest number of patients were observed in the United States in the same year.

The Psoriatic Arthritis Market Analysis Report provides historical as well as forecasted epidemiological analysis segmented into: 

• Prevalent cases of Psoriatic Arthritis
• Diagnosed cases of Psoriatic Arthritis
• Age-specific cases of Psoriatic Arthritis
• Gender-specific cases of Psoriatic Arthritis
• Severity-specific Psoriatic Arthritis Prevalence 

Get a complete epidemiological segmentation @ Psoriatic Arthritis Epidemiological Analysis 

Psoriatic Arthritis Treatment Market 

Advances in the knowledge of pathogenesis have led to the development of novel biologics beyond anti-tumor necrosis factors (TNFs). However, there is still a major proportion of patients who may not respond to certain treatment options. Therefore, the current Psoriatic Arthritis treatment strategy emphasizes a target-to-target approach to the prevalent domains. 

For mild Psoriatic Arthritis patients, treatment with NSAIDs, corticosteroids, glucocorticoids, and oral small molecules (OSMs) like methotrexate, sulfasalazine, leflunomide, cyclosporine, or apremilast is recommended. However, it is recommended to use TNF inhibitors for severe cases, followed by interleukins inhibitors (IL-23 and IL-17), PDE4 inhibitors, and JAK inhibitors.

As per Delveinsight's analysis, the evolving Psoriatic Arthritis treatment landscape, availability of alternatives with improved safety and efficacy profiles, and better results are all set to hinder the use of NSAIDs. Nevertheless, OSMs are likely to continue to retain their market position because of their affordability and demand despite being sidelined by TNFs during the forecast period. The active Psoriatic Arthritis patients, despite treatment with OSM, should switch to a biologic (TNFi, IL-17, or IL-12/23 inhibitor). Still, alternative OSMs can be considered for patients with contraindications to TNFis, those without evidence of severe disease, and those who prefer oral therapy. Guidelines advocate the preferential use of TNFis over abatacept, tofacitinib, IL-17 inhibitors, and IL-12/23 inhibitors in this situation.

Biologics dominate the Psoriatic Arthritis market in the current scenario, capturing more than half the revenue share. Further, the drug class not only expects to retain its dominance but is also anticipated to witness the fastest growth during the forecast period. Among the biologics, TNF-alpha inhibitors Enbrel, Humira, and Remicade have long-held dominant positions in the Psoriatic Arthritis market. However, the market leaders are about to face patent expirations and consequent biosimilar launches. As a result, payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and continuing market erosion for first-generation TNF-alpha inhibitors. Nevertheless, this erosion rate is likely to be gradual initially, as both physicians and payers are not likely to advocate patient switching.

The Psoriatic Arthritis market has become increasingly competitive as more biologics come up, ever since the Food and Drug Administration (FDA) granted Enbrel (etanercept) marketing authorization to treat the disease in 2002. Also, with the emergence of numerous treatment options, the Psoriatic Arthritis treatment guidelines have been further updated to reflect the improved efficacy and safety of these newer medications in the market. 

Currently, Psoriatic Arthritis pipeline products are in phases II and III of clinical development. It includes Skyrizi/ Risankizumab (AbbVie), Bimekizumab (UCB Biopharma), Brepocitinib (Pfizer), and others. It is expected that these drugs would expand the Psoriatic Arthritis market size during the forecast period. Rising awareness of the disease, evolving patient research perspective, support from government policies, funds, approvals, development of animal models, and emerging research would significantly drive the Psoriatic Arthritis market in the forecast period (2021–2030). 

Scope of the Psoriatic Arthritis Market Insight Report 

• Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 
• Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
• Psoriatic Arthritis Markets Segmentation: By Geographies and By Psoriatic Arthritis Therapies (Historical and Forecasted, Current and Upcoming) 
• Dominant Market Companies investigating its candidates for Psoriatic Arthritis: AbbVie, Amgen, Pfizer, Bristol-Myers Squibb, Janssen Biotech, Eli Lilly and Company, Novartis, UCB, Sun Pharma Global FZE, AltruBio, and several others. 
• Analysis: Comparative and conjoint analysis of emerging therapies. 
• Case Studies
• KOL's Views
• Analyst's View

Request for a Webex demo of the report @ Psoriatic Arthritis Therapeutics Market

Table of Contents 

Browse full report with detailed TOC with charts, figures, tables @ Psoriatic Arthritis Diagnostics Market Report

View Related Reports

• Psoriatic Arthritis Epidemiology Forecast to 2030

DelveInsight's Psoriatic Arthritis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Psoriatic Arthritis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• Psoriatic Arthritis Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Psoriatic Arthritis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Psoriatic Arthritis.

• Psoriatic Arthritis Pipeline Insight

Psoriatic Arthritis Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across 7MM. Dominant Market Companies investigating its candidates for Psoriatic Arthritis pipeline are AbbVie, Amgen, Pfizer, Bristol-Myers Squibb, Janssen Biotech, Eli Lilly and Company, Novartis, UCB, Sun Pharma Global FZE, AltruBio, and several others.

• Krabbe Disease Market

DelveInsight's Krabbe Disease Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. 

• Laryngeal Cancer Market

DelveInsight's Laryngeal Cancer Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. 

• Ornithine Transcarbamylase Deficiency Market

DelveInsight's Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease.

• Nosocomial Pneumonia Market

DelveInsight's Nosocomial Pneumonia Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. 

• Juvenile Idiopathic Arthritis Market

DelveInsight's Juvenile Idiopathic Arthritis (JIA) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

Browse Blog Posts

• Medical Devices Market Blooms as the Key MedTech Companies Continue to Bring-In Innovation
• Conditions Medical Marijuana is Anticipated to be Prescribed in the Offing

For ASCO updates, browse here:- 

• Cholangiocarcinoma Highlights: ASCO 2021
• Sarcoma Highlights: ASCO 2021
• Esophageal Squamous Cell Carcinoma Highlights: ASCO 2021
• Breast Cancer Highlights - ASCO 2021
• Pancreatic Cancer Highlights: ASCO 2021

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach. 

Contact Us:

Shruti Thakur
[email protected]   
+1(919)321-6187
www.delveinsight.com 

SOURCE DelveInsight Business Research, LLP